The addition of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) to ET has recently been associated with improved progression-free survival (PFS) and, in some cases, overall survival (OS) in patients with invasive ER+ breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.